![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Nigel Theobald
Nigel has over 25 years’ experience in healthcare and in building businesses, strategy development and its implementation and a strong network covering all aspects of pharmaceutical product development and commercialisation. He was the head of healthcare brands at Boots Group plc in 2002 before leaving to set up a series of successful businesses, including Oxford Pharmascience Group plc, which he grew over 5 years into an AIM quoted company with a market capitalisation of £40 million upon departure. Nigel formed N4 Pharma in 2014.
Company:N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel silica nanoparticle (SiNP) delivery system that is initially being directed towards pDNA/mRNA delivery in oncology. N4 Pharma listed on AIM in 2016 and is managed by an experienced team of scientists and business executives with significant know-how gained both in big pharma and other smaller, specialist pharma/biopharma discovery and development enterprises.
